Merck Biopharma Innovation Cup 2017

MerckMerck, a leading science and technology company, announced the winners of its seventh Biopharma Innovation Cup. The winning team received €20,000 for its innovative idea around the role of Natural Killer (NK) cells in cancer immunology. The Biopharma Innovation Cup is designed to support the professional development of post-graduate students and to foster innovation from a promising new generation of academic talent. It showcases Merck's deep commitment to leverage innovation, curiosity and collaboration. With more than 1,400 applications from 60 countries, this year's Biopharma Innovation Cup achieved a new record of popularity. Thirty-three participants worked hand in hand with experienced Merck researchers and managers in the biopharma field on developing business plans. For 6 days, bright minds came together at the Innovation Camp near Frankfurt, Germany, and jointly developed novel ideas into innovative project plans for drug discovery.

The winning team "Immuno-Oncology" inspired the audience with their outstanding project proposal on how to translate NK cell biology into a drug discovery project.

The team consisted of:

  • Alex Kertser (Weizmann Institute of Science, Israel)
  • Franklin Zhong (A*STAR, Singapore)
  • Kelly Moynihan (MIT, USA)
  • Patrik Andersson (Karolinska Institute, Sweden)
  • Simone Mori (The Scripps Research Institute, USA)
  • Arne Sutter (team coach)

As runner-up receiving €5,000, the team "Medicinal Chemistry" was chosen with an innovative proposal on DNA-encoded libraries.

The team consisted of:

  • Adam McCallum (Georgia Institute of Technology, USA)
  • Anna Rydzik (LMU Munich, Germany)
  • Josua Jordi (Harvard, USA)
  • Rüdiger Borrmann (ETH Zürich, Switzerland)
  • Wilian Cortopassi (UCSF, USA)
  • Henning Böttcher (team coach)

The initiative has won several innovation awards over the years, including the Edison Award 2017, Stevie Gold Award 2017, German Industry Innovation Award 2015 and the German Idea Award 2014. More detailed information on the Biopharma Innovation Cup can be found at Biopharma Open Innovation Portal.

"The Biopharma Innovation Cup is getting increasingly popular at innovation hotspots all over the world from year to year. We are happy to offer young talents this development opportunity," said Dr Ulrich Betz, Vice President of Innovation & Entrepreneurship Incubator at the Healthcare business of Merck and initiator and manager of the Innovation Cup.

On the occasion of their 350th anniversary in 2018, Merck will conduct a special anniversary edition of the Innovation Cup, covering topics in Life Science and Performance Materials in addition to Healthcare. Applications to participate in the 2018 edition of the cup can be submitted starting October 01, 2017, here: http://innovationcup.merckgroup.com

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. The company holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Novartis confirms 5 year data for first and only f…

Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension stud...

Researchers develop microneedle patch for flu vacc…

A National Institutes of Health-funded study led by a team at the Georgia Institute of Technology and Emory University has shown that an influenza vaccine can produce rob...

Jardiance® (empagliflozin) analysis reinforces est…

An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (...

Alzheimer's and Parkinson's spurred by same enzyme

Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors. But at ...

Researchers publish new findings on influence of h…

Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known. In a newly published study, Cleveland Cli...

Merck awards €1.25 million to research projects th…

Merck, a leading science and technology company, today announced its commitment to award €1.25 million to research projects in the field of fertility, supporting the adva...

FDA tackles drug competition to improve patient ac…

Today, the U.S. Food and Drug Administration is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower...

Trials show unique stem cells a potential asthma t…

A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma. The Mo...

Roche acquires mySugr to form a leading open platf…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. Counting more than one million users globally...

Older Americans don't get - or seek - enough help …

The majority of Americans over age 50 take two or more prescription medicines to prevent or treat health problems, and many of them say the cost weighs on their budget, a...

Novartis CAR-T cell therapy CTL019 unanimously (10…

Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisag...

New brain cancer drug targets revealed

Researchers from Case Western Reserve University School of Medicine and The Cleveland Clinic designed a way to screen brain tumor cells and identify potential drug target...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]